BlossomHill Therapeutics, Inc. (BLSM) — Stock Price, Chart & Analysis
BlossomHill Therapeutics, Inc. (BLSM) is a Healthcare stock currently trading at $25.25, down 5.78% on the day. It carries a market capitalization of $802.57M. Over the past 52 weeks, BLSM has traded between $15.25 and $27.99. BlossomHill Therapeutics, Inc. does not currently pay a regular dividend. View the live BLSM chart, technical opinion, analyst ratings, fundamentals and latest news below.
BlossomHill Therapeutics, Inc. (BLSM) key data
| Price | $25.25 |
| Change (today) | -5.78% |
| Previous close | $26.8 |
| Market cap | $802.57M |
| EPS (TTM) | $-2.49 |
| 52-week high | $27.99 |
| 52-week low | $15.25 |
| Avg. volume | 277.5K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about BlossomHill Therapeutics, Inc. (BLSM)
How much does one share of BlossomHill Therapeutics, Inc. cost?
As of the latest update, one share of BlossomHill Therapeutics, Inc. (BLSM) trades at $25.25 (-5.78% today).
What is BlossomHill Therapeutics, Inc.'s market cap?
BlossomHill Therapeutics, Inc. has a market capitalization of approximately $802.57M.
What is BlossomHill Therapeutics, Inc.'s earnings per share (EPS)?
BlossomHill Therapeutics, Inc.'s trailing twelve-month EPS is $-2.49.
Does BlossomHill Therapeutics, Inc. pay a dividend?
BlossomHill Therapeutics, Inc. does not currently pay a regular dividend.
What is BlossomHill Therapeutics, Inc.'s 52-week trading range?
Over the past year, BLSM has traded between $15.25 and $27.99.
What is the analyst price target for BlossomHill Therapeutics, Inc.?
The mean analyst price target for BlossomHill Therapeutics, Inc. is $35.40. This is informational only and not investment advice.
Latest BlossomHill Therapeutics, Inc. (BLSM) news
- BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial UpdateNews · Sep 15, 2026
- BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment ConferenceNews · Sep 3, 2026
- BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung CancerNews · Sep 1, 2026
- Insiders Are Betting Big on These 3 Healthcare StocksNews · Aug 31, 2026
- BlossomHill Therapeutics Reports Second Quarter 2026 Financial ResultsNews · Sep 18, 2026
- BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung CancerNews · Sep 15, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live BLSM dashboard…